A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
REGULATORY
Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
Japan’s health ministry approved a batch of medicines for broader labels on February 9 including Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD). Jardiance has been available in Japan for the indication of…
To read the full story
Related Article
- Opdivo, Olumiant, Dupixent Now in Line for Label Expansions
February 6, 2024
- Jardiance’s CKD Indication in Line for Japan Approval with Key Panel Nod
January 29, 2024
REGULATORY
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
- Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
- Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
November 6, 2025
- MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
- Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
November 6, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…